An observational study in Thrombosis and Venous Catheterization, sponsored by Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta · Observational
The aim is to determine the prevalence of catheter-related thrombosis (CRT) in hospitalized patients carrying PICC, FICC, CICC, and midline catheters through a multicenter, standardized prevalence study. To achieve this, a cross-sectional study with prospective data collection will be conducted, including, through consecutive sampling to minimize selection bias, all hospitalized patients over 18 years of age from both general wards and critical care units who have had one of these catheters in place for at least 7 days. During data collection, an ultrasound examination of the catheter insertion site will be performed in order to rule out the presence of thrombotic complications.
955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.
This study's planned enrollment of 500 is above the median of 173 across 384 observational studies indexed under Thrombosis.
Browse Thrombosis studies →Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta is the lead sponsor of 31 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study will be conducted across the following centers: Complejo Hospitalario Universitario Nuestra Señora de Candelaria, Hospital del Mar, Hospital Sant Joan de Déu-Althaia, Hospital Universitari Joan XXIII, Hospital Universitario de Navarra, Hospital Universitario Doctor Josep Trueta, Hospital Universitario Donostia, Hospital Universitario Mutua Terrassa, Hospital Universitario Son Espases, Policlínica Gipuzkoa, and Hospital de Navarra. Participation will include hospital institutions with an Infusion and Vascular Access Unit (IVAU) that has institutionally recognized expertise in the detection of catheter-related thrombosis (CRT).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Overall prevalence of catheter-related thrombosis
Number of patients with CRT / total number of patients evaluated) × 100
Time frame: From the beginning of the cutoff to the end of the cutoff at 4 weeks
Symptomatic CRT
(Number of CRT cases with ≥1 clinical sign / total number of CRT cases) × 100
Time frame: From the beginning of the cutoff to the end of the cutoff at 4 weeks
Asymptomatic CRT
(Number of CRT cases without clinical signs / total number of CRT cases) × 100
Time frame: From the beginning of the cutoff to the end of the cutoff at 4 weeks
Superficial CRT
Number of superficial CRT cases / total number of CRT cases) × 100
Time frame: From the beginning of the cutoff to the end of the cutoff at 4 weeks
Deep CRT
Number of deep CRT cases / total number of CRT cases) × 100
Time frame: From the beginning of the cutoff to the end of the cutoff at 4 weeks
Prevalence by responsible service
(Number of CRT cases in each service category / total number of patients evaluated in that service) × 100
Time frame: From the beginning of the cutoff to the end of the cutoff at 4 weeks
Time from implantation to CRT diagnosis
Mean, SD, median, and IQR (interquartile range) of elapsed days
Time frame: From the beginning of the cutoff to the end of the cutoff at 4 weeks
Distribution by implanting operator
Number of CRT cases by implanting operator / total number of CRT cases × 100
Time frame: From the beginning of the cutoff to the end of the cutoff at 4 weeks
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Jun 2026, 0 months later.
Of 160 non-industry observational studies under Thrombosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 114. This study's planned 0 months is below that.
Counting every sponsor, half of 189 studies reached it within 31 months; a quarter within 12 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta